

Resource Summary Report

Generated by [NIF](#) on Sep 18, 2026

NGP

RRID:CVCL_2141

Type: Cell Line

Proper Citation

RRID:CVCL_2141

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_2141

Proper Citation: RRID:CVCL_2141

Description: Cell line NGP is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Neuroblastoma

Defining Citation: [PMID:922665](#), [PMID:6888561](#), [PMID:8490657](#), [PMID:9283597](#), [PMID:11550280](#), [PMID:15150091](#), [PMID:15892104](#), [PMID:16822308](#), [PMID:18724359](#), [PMID:20655465](#), [PMID:22213050](#), [PMID:23202128](#), [PMID:24466371](#), [PMID:28350380](#)

Comments: Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: NGP

Cross References: CLO:CLO_0037091, BioSample:SAMN03473431, cancercellines:CVCL_2141, Cell_Model_Passport:SIDM01785, Cosmic:717421, Cosmic:923823, Cosmic:930071, Cosmic:1019937, Cosmic:1109120, Cosmic:1161999, Cosmic:1167422, Cosmic:1167988, Cosmic:1526637, Cosmic:2058106, Cosmic:2393638, DepMap:ACH-001366, DSMZ:ACC-676, DSMZCellDive:ACC-676, GEO:GSM453633, GEO:GSM692865, GEO:GSM2371249, GEO:GSM2394382, GEO:GSM3145577, GEO:GSM3145726, GEO:GSM4104589, GEO:GSM4104590, GEO:GSM4105333, GEO:GSM4105334, GEO:GSM4105335, GEO:GSM4105336, GEO:GSM4105337, IARC_TP53:23601, LINCS_HMS:51099, LINCS_LDP:LCL-2103, Progenetix:CVCL_2141,

Wikidata:Q54930471

ID: CVCL_2141

Record Creation Time: 20220427T221338+0000

Record Last Update: 20260913T005611+0000

Ratings and Alerts

No rating or validation information has been found for NGP.

No alerts have been found for NGP.

Data and Source Information

Source: [CelloSaurus](#)

Usage and Citation Metrics

We found 16 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Pommerenke C, et al. (2026) Neuronal differentiation of neuroblastoma cell lines for neurological disease modeling. iScience, 29(7), 116469.

Ludwig M, et al. (2026) YAP1 Enhances Mesenchymal-Type Gene Expression in Human Adrenergic-Type Neuroblastoma Cells. Cancers, 18(3).

Montuori G, et al. (2025) Extrachromosomal DNA-Driven Oncogene Dosage Heterogeneity Promotes Rapid Adaptation to Therapy in MYCN-Amplified Cancers. Cancer discovery, 15(10), 2054.

Azfar M, et al. (2025) The polyamine transporter ATP13A3 mediates difluoromethylornithine-induced polyamine uptake in neuroblastoma. Molecular oncology, 19(3), 913.

Thombare K, et al. (2024) METTL3/MYCN cooperation drives neural crest differentiation and provides therapeutic vulnerability in neuroblastoma. The EMBO journal, 43(24), 6310.

Lee WG, et al. (2024) Differential RNA Expression Between Metastatic and Primary Neuroblastoma Cells. The Journal of surgical research, 298, 240.

Lee JY, et al. (2023) Identification and targeting of protein tyrosine kinase 7 (PTK7) as an immunotherapy candidate for neuroblastoma. Cell reports. Medicine, 4(6), 101091.

Rösch L, et al. (2023) ERBB and P-glycoprotein inhibitors break resistance in relapsed neuroblastoma models through P-glycoprotein. Molecular oncology, 17(1), 37.

Radosevich MT, et al. (2023) Antigen density quantification of cell-surface immunotherapy targets by flow cytometry: Multi-antigen assay of neuroblastoma bone marrow metastasis. STAR protocols, 4(4), 102709.

Heitzeneder S, et al. (2022) GPC2-CAR T cells tuned for low antigen density mediate potent activity against neuroblastoma without toxicity. Cancer cell, 40(1), 53.

Papadopoulos D, et al. (2022) MYCN recruits the nuclear exosome complex to RNA polymerase II to prevent transcription-replication conflicts. Molecular cell, 82(1), 159.

Arlt B, et al. (2021) Inhibiting phosphoglycerate dehydrogenase counteracts chemotherapeutic efficacy against MYCN-amplified neuroblastoma. International journal of cancer, 148(5), 1219.

Buongervino S, et al. (2021) Antibody-Drug Conjugate Efficacy in Neuroblastoma: Role of Payload, Resistance Mechanisms, Target Density, and Antibody Internalization. Molecular cancer therapeutics, 20(11), 2228.

Morita K, et al. (2020) Allosteric Activators of Protein Phosphatase 2A Display Broad Antitumor Activity Mediated by Dephosphorylation of MYBL2. Cell, 181(3), 702.

Cossa G, et al. (2020) Localized Inhibition of Protein Phosphatase 1 by NUAK1 Promotes Spliceosome Activity and Reveals a MYC-Sensitive Feedback Control of Transcription. Molecular cell, 77(6), 1322.

Bosse KR, et al. (2017) Identification of GPC2 as an Oncoprotein and Candidate Immunotherapeutic Target in High-Risk Neuroblastoma. Cancer cell, 32(3), 295.